Organization
University of Basel
1 abstract
3 posters
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,